论文部分内容阅读
目的:探讨分析吉非替尼应用于晚期肺腺癌患者的临床疗效。方法:选取我院42例晚期肺腺癌患者42例并分为治疗组与观察组,每组各21例。两组患者均给予放射治疗,治疗组患者在此基础上给予吉非替尼口服治疗,观察组患者给予紫杉醇(多西他赛)、卡铂药物治疗。记录两组患者近期疗效、生存情况及不良反应情况并进行对比。结果:治疗组患者1、2年生存率、中位生存期及95%CI均明显多于对照组(P<0.05,差异明显);治疗组患者的CR、PR、PD及RR明显优于观察组(P<0.05);治疗组患者不良反应出现概率明显较高(P<0.05),但其严重程度无明显差异(P>0.05)。结论:对晚期肺腺癌患者应用吉非替尼可以明显改善近期治疗效率、延长生存期,但也可提高不良反应出现机率。
Objective: To investigate the clinical efficacy of gefitinib in patients with advanced lung adenocarcinoma. Methods: 42 cases of advanced lung adenocarcinoma in our hospital were selected and divided into treatment group and observation group, 21 cases in each group. Radiotherapy was given to both groups, and patients in the treatment group were given gefitinib orally on this basis. Patients in the observation group were given paclitaxel (docetaxel) and carboplatin. The short-term efficacy, survival and adverse reactions of the two groups were recorded and compared. Results: The 1-year and 2-year survival rates, median survival and 95% CI of the treatment group were significantly higher than those of the control group (P <0.05, significant difference); CR, PR, PD and RR of the treatment group were significantly better than those of the control group (P <0.05). The incidence of adverse reactions in the treatment group was significantly higher (P <0.05), but the severity was no significant difference (P> 0.05). Conclusion: The application of gefitinib in patients with advanced lung adenocarcinoma can significantly improve the short-term treatment efficiency and prolong survival, but also increase the chance of adverse reactions.